Conference Call with Natco Pharma Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
Highlights: NATCO records INR 415.2 Crore consolidated revenue and INR 65.1 Crore of profit after tax, for the Second Quarter, FY2021-22. NATCO Pharma has recorded consolidated total revenue of INR 415.2 Crore for the Second quarter ended on 30th September, 2021, as against INR 827.90 Crore for the same period last year. The net profit for the period, on a consolidated basis, was INR 65.1 Crores as against INR 203.90 Crore same period last year. The decline in revenue and profits compared to last year quarter is primarily due to a one-off contribution in prior period earnings. The company is poised for growth during latter half of this financial year and confident of a strong rebound in business. During this quarter, Lenalidomide product in Canada and Everolimus higher strength product in USA were launched. The revenues from these products will be realized in immediate quarters. The company is well prepared for its major launch of Lenalidomide in USA during Q4 of this financial year. Result PDF